Mayoly, the independent French pharmaceutical group, has inaugurated two new state-of-the-art production lines dedicated to Meteospasmyl at its historic site in Dammarie-les-Lys.
A recognised leader in soft-gel capsule manufacturing, Mayoly is strengthening both its industrial expertise and its contribution to the strategic sovereignty of the French pharma sector.
With an investment of €15 million completed in just 18 months, the project significantly expands production capacity — now exceeding 25 million boxes per year — to support rising demand in France and across more than 50 international markets.
These next-generation lines also reflect the group’s broader commitments:
- Industrial sovereignty through the consolidation of global Meteospasmyl production in France
- Environmental performance, with a 15% reduction in energy consumption and reduced use of PVC and aluminium in blister packaging
- Local economic growth, with around 40 new qualified jobs expected by the end of 2026
For the Île-de-France region, this expansion underscores Mayoly’s long-standing industrial presence and its ambition to drive innovation, competitiveness, and sustainable growth within the French pharmaceutical landscape.